Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | NOS1 | P29475 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3614154 | 0.87 | NOS1 (0.53) | MAPTSMN1; SMN2TSHRCYP3A4NOS1 | |
| SCHEMBL11606284 | 0.86 | MAPT (0.59) | MAPTSMN1; SMN2TSHRCYP3A4NOS1 | |
| SCHEMBL27153006 | 0.80 | NOS1 (0.53) | MAPTSMN1; SMN2TSHRCYP3A4NOS1 | |
| SCHEMBL28673208 | 0.80 | MAPT (0.53) | MAPTSMN1; SMN2TSHRCYP3A4NOS1 | |
| SCHEMBL12282300 | 0.80 | NOS1 (0.53) | MAPTSMN1; SMN2TSHRCYP3A4NOS1 | |
| SCHEMBL23275822 | 0.80 | NOS1 (0.53) | MAPTSMN1; SMN2TSHRCYP3A4NOS1 | |
| SCHEMBL30293811 | 0.80 | MAPT (0.53) | MAPTSMN1; SMN2TSHRCYP3A4NOS1 | |
| SCHEMBL11607974 | 0.78 | TSHR (0.43) | MAPTSMN1; SMN2TSHRCYP3A4NOS1 | |
| SCHEMBL6127809 | 0.76 | MAPT (0.48) | MAPTNOS1KDM4ECYP1A2HPGD | |
| SCHEMBL9687765 | 0.74 | MAPT (0.47) | MAPTSMN1; SMN2TSHRCYP3A4NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577536-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | Hotspot Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2024044730-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-0189473-B1 | NEW DOPAMINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE AS MEDICINAL PRODUCTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-05-27 | — | — | EP | disclosed |
| US-4958026-A | HYPOTENSIVE AGENTS | SCHERING AKTIENGESLLSCHAFT (DE) | 1990-09-18 | — | — | US | disclosed |
| EP-0189473-A1 | NEW DOPAMINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE AS MEDICINAL PRODUCTS. | SCHERING AG (DE) | 1986-08-06 | — | — | EP | disclosed |
| WO-1986001204-A1 | NEW DOPAMINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE AS MEDICINAL PRODUCTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | MAPT 2561/4885SMN1; SMN2 4459/4885TSHR 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.